Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2006

01-05-2006 | Original article

Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results

Authors: Cristina Nanni, Elena Zamagni, Mohsen Farsad, Paolo Castellucci, Patrizia Tosi, Delia Cangini, Eugenio Salizzoni, Romeo Canini, Michele Cavo, Stefano Fanti

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2006

Login to get access

Abstract

Purpose

Multiple myeloma (MM) is a malignant B cell and plasma cell disorder which involves the skeleton in more than 80% of patients at diagnosis. The aim of this study was to compare whole-body X-ray (WBXR), MRI and 18F-FDG PET/CT in patients with MM.

Methods

The study population comprised 28 newly diagnosed MM patients. Findings of 18F-FDG PET/CT were compared with those of WBXR and MRI with regard to the number and site of lesions detected.

Results

Comparing 18F-FDG PET/CT and WBXR, it was found that in 16/28 pts (57%) 18F-FDG PET/CT detected more lesions, all of which were located in the skeleton. Nine of these 16 patients had a completely negative WBXR survey. In 12/28 pts (43%) the two methods yielded equivalent findings. Comparing 18F-FDG PET/CT and MRI, it was found that in 7/28 pts (25%), 18F-FDG PET/CT detected more lytic bone lesions, all of which were located outside the field of view of MRI (bone lesions in six cases and a soft tissue lesion in one). In 14/28 pts (50%), 18F-FDG PET/CT and MRI detected the same number of lesions in the spine and pelvis, while in 7/28 pts (25%) MRI detected an infiltrative pattern in the spine whereas 18F-FDG PET/CT was negative.

Conclusion

18F-FDG PET/CT appears to be more sensitive than WBXR for the detection of small lytic bone lesions, whereas it has the same sensitivity as MRI in detecting bone disease of the spine and pelvis. On the other hand, MRI may be superior to 18F-FDG PET/CT in diagnosing an infiltrative pattern in the spine. Therefore, careful evaluation of MM bone disease at diagnosis should include both MRI of the spine and 18F-FDG PET/CT.
Literature
2.
go back to reference Bataille R, Manolagas SC, Berenson JR. Pathogenesis and management of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 1997;11:349–361PubMedCrossRef Bataille R, Manolagas SC, Berenson JR. Pathogenesis and management of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 1997;11:349–361PubMedCrossRef
3.
go back to reference Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 2003;123:758–769PubMedCrossRef Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 2003;123:758–769PubMedCrossRef
4.
go back to reference Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004;6:439–444PubMedCrossRef Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004;6:439–444PubMedCrossRef
5.
6.
go back to reference Blade J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years: report of 10 cases and review of the literature. Arch Intern Med 1996;156:1463–1468PubMedCrossRef Blade J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years: report of 10 cases and review of the literature. Arch Intern Med 1996;156:1463–1468PubMedCrossRef
7.
go back to reference Hallek M, Bergsagel PF, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3–21PubMed Hallek M, Bergsagel PF, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3–21PubMed
8.
go back to reference Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 1992;6:273–284PubMed Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 1992;6:273–284PubMed
9.
go back to reference Schwartz GG. Multiple myeloma: clusters, clues, and dioxins. Cancer Epidemiol Biomarkers Prev 1997;6:49–56PubMed Schwartz GG. Multiple myeloma: clusters, clues, and dioxins. Cancer Epidemiol Biomarkers Prev 1997;6:49–56PubMed
10.
go back to reference Lecouvet FE, Malghem J, Michaux L, Maldague B, Ferrant A, Michaux JL, et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol 1999;106:35–39PubMedCrossRef Lecouvet FE, Malghem J, Michaux L, Maldague B, Ferrant A, Michaux JL, et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol 1999;106:35–39PubMedCrossRef
11.
go back to reference Umeda M, Adachi Y, Tomiyama J, Takasaki M, Shin K, Mori M, et al. Bone lesions in elderly multiple myeloma. Nippon Ronen Igakkai Zasshi 2002;39:631–638PubMed Umeda M, Adachi Y, Tomiyama J, Takasaki M, Shin K, Mori M, et al. Bone lesions in elderly multiple myeloma. Nippon Ronen Igakkai Zasshi 2002;39:631–638PubMed
12.
go back to reference Kitano M, Ogata A, Sekiguchi M, Hamano T, Sano H. Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease. J Bone Miner Metab 2005;23:48–52PubMedCrossRef Kitano M, Ogata A, Sekiguchi M, Hamano T, Sano H. Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease. J Bone Miner Metab 2005;23:48–52PubMedCrossRef
13.
go back to reference Harousseau JL, Shaughnessy J Jr, Richardson P. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2004;237–256 Harousseau JL, Shaughnessy J Jr, Richardson P. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2004;237–256
14.
go back to reference Woodruff RK, Wadsworth J, Malpas JS, Tobias JS. Clinical staging in multiple myeloma. Br J Haematol 1979;42:199–205PubMed Woodruff RK, Wadsworth J, Malpas JS, Tobias JS. Clinical staging in multiple myeloma. Br J Haematol 1979;42:199–205PubMed
15.
go back to reference Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Haematol J 2003;4:379–398 Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Haematol J 2003;4:379–398
16.
go back to reference Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842–854PubMedCrossRef Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842–854PubMedCrossRef
17.
go back to reference Angtuaco EJ, Fassas AB, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology 2004;231:11–23PubMedCrossRef Angtuaco EJ, Fassas AB, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology 2004;231:11–23PubMedCrossRef
18.
go back to reference Walker RE, Eustace SJ. Whole-body magnetic resonance imaging: techniques, clinical indications and future applications. Semin Musculoskelet Radiol 2001;5:5–19PubMedCrossRef Walker RE, Eustace SJ. Whole-body magnetic resonance imaging: techniques, clinical indications and future applications. Semin Musculoskelet Radiol 2001;5:5–19PubMedCrossRef
19.
go back to reference Vogler JB, Murphy WA. Bone marrow imaging. Radiology 1988;168:679–693PubMed Vogler JB, Murphy WA. Bone marrow imaging. Radiology 1988;168:679–693PubMed
20.
21.
go back to reference Tertti R, Alanen A, Remes K. The value of magnetic resonance imaging in screening myeloma lesions of the lumbar spine. Br J Haematol 1995;91:658–660PubMed Tertti R, Alanen A, Remes K. The value of magnetic resonance imaging in screening myeloma lesions of the lumbar spine. Br J Haematol 1995;91:658–660PubMed
22.
go back to reference Ghanema N, Uhla M, Brink IB, Schaeer O, Kelly T, Moser E, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 2005;55:41–55CrossRef Ghanema N, Uhla M, Brink IB, Schaeer O, Kelly T, Moser E, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 2005;55:41–55CrossRef
23.
go back to reference Schmidt GP, Schoenberg SO, Reiser MF, Baur-Melnyk A. Whole-body MR imaging of bone marrow. Eur J Radiol 2005;55:33–40PubMedCrossRef Schmidt GP, Schoenberg SO, Reiser MF, Baur-Melnyk A. Whole-body MR imaging of bone marrow. Eur J Radiol 2005;55:33–40PubMedCrossRef
24.
go back to reference Baur-Melnyk A, Reiser M. [Staging of multiple myeloma with MRI: comparison to MSCT and conventional radiography]. Radiologe 2004;44:874–881PubMedCrossRef Baur-Melnyk A, Reiser M. [Staging of multiple myeloma with MRI: comparison to MSCT and conventional radiography]. Radiologe 2004;44:874–881PubMedCrossRef
25.
go back to reference Moulopoulos LA, Varma DG, Dimopoulos MA, Leeds NE, Kim EE, Johnston DA, et al. Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 1992;185:833–840PubMed Moulopoulos LA, Varma DG, Dimopoulos MA, Leeds NE, Kim EE, Johnston DA, et al. Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 1992;185:833–840PubMed
26.
go back to reference Baur A, Stabler A, Nagel D, Lamerz R, Bartl R, Hiller E, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002;95:1334–1345PubMedCrossRef Baur A, Stabler A, Nagel D, Lamerz R, Bartl R, Hiller E, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002;95:1334–1345PubMedCrossRef
27.
go back to reference Moulopolous LA, Dimopoulos MA. Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood 1997;90:2127–2147 Moulopolous LA, Dimopoulos MA. Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood 1997;90:2127–2147
28.
go back to reference Moulopoulos LA, Dimopoulos MA, Smith T, Weber D, Delasalle KB, Libshitz HI, et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 1995;13:251–256PubMed Moulopoulos LA, Dimopoulos MA, Smith T, Weber D, Delasalle KB, Libshitz HI, et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 1995;13:251–256PubMed
29.
go back to reference Moulopoulos LA, Gika D, Anagnostopoulos A, Delasalle K, Weber D, Alexanian R, Dimopoulos MA.Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.Ann Oncol 2005;16:1824–1828PubMedCrossRef Moulopoulos LA, Gika D, Anagnostopoulos A, Delasalle K, Weber D, Alexanian R, Dimopoulos MA.Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.Ann Oncol 2005;16:1824–1828PubMedCrossRef
30.
go back to reference Mariette X, Zagdanski AM, Guermazi A, Bergot C, Arnould A, Frija J, et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol 1999;104:723–729PubMedCrossRef Mariette X, Zagdanski AM, Guermazi A, Bergot C, Arnould A, Frija J, et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol 1999;104:723–729PubMedCrossRef
31.
go back to reference Lecouvet FE, Malghem J, Michaux L, Maldague B, Ferrant A, Michaux JL, et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol 1999;106:35–39PubMedCrossRef Lecouvet FE, Malghem J, Michaux L, Maldague B, Ferrant A, Michaux JL, et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol 1999;106:35–39PubMedCrossRef
32.
go back to reference Moulopolous LA, Dimopoulos MA, Alexanian R, Leeds NE, Libshitz HI. Multiple myeloma: MR patterns of response to treatment. Radiology 1994;193:441–446 Moulopolous LA, Dimopoulos MA, Alexanian R, Leeds NE, Libshitz HI. Multiple myeloma: MR patterns of response to treatment. Radiology 1994;193:441–446
33.
go back to reference Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol 2002;31:690–694PubMedCrossRef Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol 2002;31:690–694PubMedCrossRef
34.
go back to reference Schirrmeister H, Bommer M, Buck AK, Muller S, Messer P, Bunjes D, et al. Initial results in the assessment of multiple myeloma using FDG-PET. Eur J Nucl Med 2002;29:361–366CrossRef Schirrmeister H, Bommer M, Buck AK, Muller S, Messer P, Bunjes D, et al. Initial results in the assessment of multiple myeloma using FDG-PET. Eur J Nucl Med 2002;29:361–366CrossRef
35.
go back to reference Durie GM, Waxman AD, D’Agnolo A, Williams CM. Whole body 18F-FDG-PET identifies high-risk myeloma. J Nucl Med 2002;43:1457–1463PubMed Durie GM, Waxman AD, D’Agnolo A, Williams CM. Whole body 18F-FDG-PET identifies high-risk myeloma. J Nucl Med 2002;43:1457–1463PubMed
Metadata
Title
Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results
Authors
Cristina Nanni
Elena Zamagni
Mohsen Farsad
Paolo Castellucci
Patrizia Tosi
Delia Cangini
Eugenio Salizzoni
Romeo Canini
Michele Cavo
Stefano Fanti
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2006
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-005-0004-3

Other articles of this Issue 5/2006

European Journal of Nuclear Medicine and Molecular Imaging 5/2006 Go to the issue